On Tuesday, Iterum Therapeutics Plc (NASDAQ: ITRM) opened lower -5.23% from the last session, before settling in for the closing price of $0.72. Price fluctuations for ITRM have ranged from $0.66 to $3.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 29.27% annually for the last half of the decade. Company’s average yearly earnings per share was noted 51.12% at the time writing. With a float of $43.68 million, this company’s outstanding shares have now reached $44.66 million.
Iterum Therapeutics Plc (ITRM) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Iterum Therapeutics Plc is 2.19%, while institutional ownership is 4.57%. The most recent insider transaction that took place on Aug 08 ’25, was worth 10,854. In this transaction Director of this company bought 15,000 shares at a rate of $0.72, taking the stock ownership to the 235,001 shares.
Iterum Therapeutics Plc (ITRM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 51.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.64% during the next five years compared to 29.27% growth over the previous five years of trading.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Check out the current performance indicators for Iterum Therapeutics Plc (ITRM). In the past quarter, the stock posted a quick ratio of 2.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.10 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was better than the volume of 0.6 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.09%.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 3.41%, which indicates a significant increase from 1.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0573 in the past 14 days, which was lower than the 0.0669 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8718, while its 200-day Moving Average is $1.2895. However, in the short run, Iterum Therapeutics Plc’s stock first resistance to watch stands at $0.7137. Second resistance stands at $0.7440. The third major resistance level sits at $0.7609. If the price goes on to break the first support level at $0.6665, it is likely to go to the next support level at $0.6496. The third support level lies at $0.6193 if the price breaches the second support level.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
There are currently 44,657K shares outstanding in the company with a market cap of 30.52 million. Presently, the company’s annual sales total 0 K according to its annual income of -24,770 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -6,510 K.
